Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · July 04, 2021

Effects of Fremanezumab in Chronic Migraine With Comorbid Depression

Headache

 

Additional Info

Disclosure statements are available on the authors' profiles:

Headache
Effects of Fremanezumab in Patients With Chronic Migraine and Comorbid Depression: Subgroup Analysis of the Randomized HALO CM Study
Headache 2021 Apr 01;61(4)662-672, RB Lipton, JM Cohen, M Galic, MJ Seminerio, PP Yeung, E Aycardi, ME Bigal, K Bibeau, DC Buse

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading